← Eichor
Study identifier: NCT06349642 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Condition: Early Stage Triple-Negative Breast Carcinoma · Metastatic Bladder Urothelial Carcinoma · Metastatic Cervical Carcinoma  ·  Sponsor: Mayo Clinic

PhaseN/A
Planned participants324
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Referral Office  ·  855-776-0015  ·  mayocliniccancerstudies@mayo.edu

Always discuss trial participation with your own doctor first.

Locations (3)

Mayo Clinic in ArizonaPhoenix, Arizona, United StatesRecruiting
Mayo Clinic in FloridaJacksonville, Florida, United StatesRecruiting
Mayo Clinic in RochesterRochester, Minnesota, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06349642